



# Implantica mourns the death of board member Prof. Dr. Klaus Neftel

**Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces with regret that Prof. Dr. Klaus Neftel, a member of the Implantica Board of Directors, has passed away.**

Prof. Dr. Neftel was appointed as a director of the Implantica Group in January 2018. He was the former Chief of Internal Medicine at the Ziegler Hospital in Bern as well as a Professor at the University of Bern. He was also the Editor of the Swiss Medical Forum and previously developed and lead an internet portal for a nationwide CME (Continued Medical Education) program.

Dr. Peter Forsell, Implantica Founder and CEO, stated, "I am greatly saddened by Klaus's passing. He was a big supporter of Implantica's technology and contributed with his broad medical experience, and I will always appreciate his dedication. We extend our deepest condolences to Klaus's family."

Liselott Kilaas, Chairman of the Board of Implantica, added, "We are grateful to Klaus for his commitment and service to Implantica. It has been a privilege for me and the other Board members to work with Klaus. He will be greatly missed."

## For further information, please contact:

Nicole Pehrsson, Chief Corporate Affairs Officer  
Telephone (CH): +41 (0)79 335 09 49  
[nicole.pehrsson@implantica.com](mailto:nicole.pehrsson@implantica.com)

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, [info@fnca.se](mailto:info@fnca.se)

*The information was sent for publication, through the agency of the contact person set out above, on September 11, 2024, at 15:30 (CEST).*

## About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energizing platform designed to power remote-controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit [www.implantica.com](http://www.implantica.com) for further information.

## About RefluxStop™

RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. Its unique mechanism of action differentiates it from

standard of care and current surgical solutions. Longer established surgical options for GORD involve encircling the food passageway to support the lower oesophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.

In contrast, the RefluxStop™ device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower oesophageal sphincter in its original, natural position.

The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

**Newsroom**

<http://www.implantica.com/media/media-kit>

**Community**

<http://ch.linkedin.com/company/implantica>

<http://www.twitter.com/implantica>

**Media Contact:**

Implantica AG

Juanita Eberhart, VP Marketing & Advocacy

M: +1 925-381-4581

[juanita.eberhart@implantica.com](mailto:juanita.eberhart@implantica.com)